{"name":"Neurop Inc.","slug":"neurop-inc","ticker":"","exchange":"","domain":"","description":"Neurop Inc. is a biotechnology company focused on developing innovative treatments for neurological disorders. The company's lead candidate, NP10679, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":99986000,"revenueGrowth":25.1,"grossMargin":77.2,"rdSpend":27888000,"netIncome":-21465000,"cash":21692000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fluoxetine (prozac)","genericName":"Fluoxetine (prozac)","slug":"fluoxetine-prozac","indication":"Major depressive disorder","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NPL-2009","genericName":"NPL-2009","slug":"npl-2009","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Fluoxetine (prozac)","genericName":"Fluoxetine (prozac)","slug":"fluoxetine-prozac","phase":"marketed","mechanism":"Fluoxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","indications":["Major depressive disorder","Obsessive-compulsive disorder","Panic disorder","Bulimia nervosa","Premenstrual dysphoric disorder"],"catalyst":""},{"name":"NPL-2009","genericName":"NPL-2009","slug":"npl-2009","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5IRjkxaXpLRTJEdml5RTFJQnBUZWNaa2xpWU91WUhXbExQYnBlM2NUNmhyTG5QRS1FbXA5OEVmUi1jOGVpdGRmU0xadWdCdTlmSmxGV1g0ZUFoY2JZTDFUOHVzYTc1TU9C?oc=5","date":"2024-04-08","type":"pipeline","source":"Built In","summary":"21 Atlanta Biotech Companies Making Waves in the Life Sciences Sector - Built In","headline":"21 Atlanta Biotech Companies Making Waves in the Life Sciences Sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPMkpWeS04WE1CV29FOXlkU1QzdEtaYmhHc2VSMDM2YjNqZ2k1MFc1LVZQQWgzdTUzMkVYMFFfMVNEU2ZCZ2RPRXpUcmZwbXozU2hCdDV3U3V0cFFCNDRoV1o0OFdOZjdGdllZeFh2ZHpMYVJBS1FYM09jNlk0SGJvaDk2V1NDd3JDeThwQ3lXWGo?oc=5","date":"2024-01-29","type":"pipeline","source":"BioWorld News","summary":"Exxel Pharma advances EX-937 for chronic cough - BioWorld News","headline":"Exxel Pharma advances EX-937 for chronic cough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPOG5qdklIZnFuRHpkQ2dKSXFIWF9WVlkzaXNOYXBkOEZLbHA3Ynhoc3dYczg2d1MtN1ItRV9CV3BGV04xYmdIQl93Q0J3N1d0Q2YtS2FWSEhBVGx6TTRNUFNMaGxOOXFQbVEtNHFhMkZiT3VPVlZXNGlpYlhyeDhjOHpGdTFYWV94UlJSZmg1b3FiN2VKZnpxTlVWcnZnQ0F0RXUyVzlVUlF2SWl0aUVSWi03OWJiY3ZqUUcyQl9JMjlieFJQNVd5SE1FZW9KZ3JpS3RxVy1EYWhPdE9JQXZmdmJLX0RSamZY?oc=5","date":"2021-12-08","type":"regulatory","source":"Business Wire","summary":"NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage - Business Wire","headline":"NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":99986000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":99986000,"period":"2025-12-31"},{"value":79906000,"period":"2024-12-31"},{"value":65421000,"period":"2023-12-31"},{"value":45520000,"period":"2022-12-31"},{"value":45183000,"period":"2021-12-31"},{"value":41138000,"period":"2020-12-31"}],"grossProfit":77220000,"grossProfitHistory":[],"rdSpend":27888000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-21465000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":21692000,"cashHistory":[],"totalAssets":105565000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}